Table 2 Characteristics of first prescribed bDMARD, comparing etanercept and other TNFis
From: Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis
Biologic | Etanercept | Other TNFi | P-value* |
|---|---|---|---|
N | 99 | 101 | |
Age at diagnosis, median years (IQR) | 5.0 (2.3–9.9) | 9.7 (3.4–13.7) | < 0.001 |
Disease duration, median years (IQR) | 7.3 (4.7–10.1) | 4.9 (3.3–8.7) | 0.001 |
Active joints at start of 1st bDMARD, median (IQR) | 2 (1–4) | 2 (1–3) | 0.592 |
Cumulative active joints, median (IQR) | 6 (3–11) | 5 (2–7) | 0.093 |
Switchers, n (%) | 49 (49) | 25 (25) | < 0.001 |
0 switch | 50 (51) | 76 (75) | 0.014 |
1 switch | 27 (27) | 12 (12) | |
2 switches | 14 (14) | 9 (9) | |
≧3 switches | 8 (8) | 4 (4) | |
Reasons for 1st switch, n (%) | |||
Inefficacy | 25 (51) | 17 (68) | 0.164 |
Other reasons than inefficacya | 24 (49) | 8 (32) | |
Disease duration before 1st bDMARD, median months (IQR) | 27.5 (5.6–71.3) | 21.5 (5.1–51.9) | 0.484 |
Treatment duration of 1st bDMARD, median months (IQR) | 24.8 (7.6–44.7) | 22.7 (11.7–31.8) | 0.540 |
- Switchers | 10.2 (5.8–31.7) | 16.2 (8.4–33.7) | 0.275 |
- Non-switchers | 35.1 (21.6–51.9) | 24.1 (14.0–30.9) | 0.002 |
csDMARD before 1st bDMARD, n (%) | 92 (93) | 81 (80) | 0.003 |
csDMARD + 1st bDMARD, n (%) | 79 (80) | 79 (78) | 0.559 |